Clinical Trial Search

Primary: The Primary Study Endpoint Was the Change in Average 24-hour Pain Score From Baseline to the 6-month Follow-up. — -1.94; -2.78; -1.59 units on a scale

Primary: Phase Ib: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period — 6; 10; 10; 5 Participants

Primary: Disease Control Rate With RECIST 1.1 Criteria — 0 Participants

Primary: Change From Baseline in Liver Cu Concentration at Week 48 (Treatment Period) — 92.8 μg/g — p=0.1002

Primary: Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12 — 0.08; -0.60; 0.07; -0.14 percent change — p=<0.0001

Primary: Carotid Femoral Pulse Wave Velocity (cfPWV) — 8.71; 7.8; 8.28 m/s

Primary: Response Rate

Primary: Functional Connectivity Strengths of Neural Networks — 0.233; 0.318 Pearson coefficient — p=0.007567

Primary: Therapeutic Responder at 3 Months — 65 Participants

Primary: Percentage of Participants With no Histologic Evidence of Anal or Anal/Peri-Anal HSIL and no Evidence of HPV-16/18 at Week 36 — 9.1 percentage of participants — p=0.8633

Primary: Determine the Efficacy of Doxycycline in Inducing Metakaryotic Cell Death in Primary Pancreatic Tumors as Measured by Pathologic Response — 8.9 Cells/g

Primary: The 8-week Evaluation of Verbal Fluency Performance After Randomization — 39.44; 41.12 score on a scale — p=<0.05

Primary: CDI Recurrence Week 8 — 4; 9; 5; 4 Participants

Primary: Number of Participants With Resolution of Active PCT by 7 Months After Start of Therapy — 9 Participants

Primary: Percent Change in Weekly Average Peak Pruritus Numeric Rating Scale (PP-NRS) From Baseline to Week 12 — -78.26; -53.66 percent change — p=<0.001